Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease

V Dartois, T Dick - Nature Reviews Drug Discovery, 2024 - nature.com
Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

[HTML][HTML] Tuberculosis treatment monitoring tests during routine practice: study design guidance

ELH MacLean, AJ Zimmer, S den Boon… - Clinical Microbiology …, 2024 - Elsevier
Scope The current tools for tuberculosis (TB) treatment monitoring, smear microscopy and
culture, cannot accurately predict poor treatment outcomes. Research into new TB treatment …

Acetic Acid Enables Molecular Enumeration of Mycobacterium tuberculosis from Sputum and Eliminates the Need for a Biosafety Level 3 Laboratory

A Palekyte, A Morkowska, O Billington… - Clinical …, 2024 - academic.oup.com
Abstract Background Improved monitoring of Mycobacterium tuberculosis response to
treatment is urgently required. We previously developed the molecular bacterial load assay …

[HTML][HTML] Accuracy of the tuberculosis molecular bacterial load assay to diagnose and monitor response to anti-tuberculosis therapy: a longitudinal comparative study …

E Musisi, S Wamutu, W Ssengooba, S Kasiinga… - The Lancet …, 2024 - thelancet.com
Background In 2018, the tuberculosis molecular bacterial load assay (TB-MBLA), a
ribosomal RNA-based test, was acknowledged by WHO as a molecular assay that could …

Quantifying Viable M. tuberculosis Safely Obviating the Need for High Containment Facilities

B Mtafya, E Musisi, P Qwaray, E Sichone… - Antibiotic Resistance …, 2024 - Springer
Mycobacterium tuberculosis is an infectious pathogen that requires biosafety level-3
laboratory for handling. The risk of transmission is high to laboratory staff, and to manage the …